Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1973 1
1984 1
1989 1
1991 2
1993 1
1996 1
1998 1
1999 2
2001 1
2003 1
2004 2
2006 2
2007 4
2008 1
2009 2
2010 3
2011 6
2012 4
2013 11
2014 16
2015 18
2016 17
2017 27
2018 30
2019 30
2020 21
2021 16
2022 15
2023 12
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 29645341

211 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
Ahn CH, Han KA, Yu JM, Nam JY, Ahn KJ, Oh TK, Lee HW, Lee DH, Kim J, Chung CH, Park TS, Kim BJ, Park SW, Park HK, Lee KJ, Kim SW, Park JH, Ko KP, Kim CH, Lee H, Jang HC, Park KS. Ahn CH, et al. Diabetes Obes Metab. 2017 May;19(5):635-643. doi: 10.1111/dom.12866. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 28026912 Clinical Trial.
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
Roussel R, Duran-García S, Zhang Y, Shah S, Darmiento C, Shankar RR, Golm GT, Lam RLH, O'Neill EA, Gantz I, Kaufman KD, Engel SS. Roussel R, et al. Diabetes Obes Metab. 2019 Apr;21(4):781-790. doi: 10.1111/dom.13574. Epub 2018 Dec 9. Diabetes Obes Metab. 2019. PMID: 30393950 Free PMC article. Clinical Trial.
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Pratley RE, Eldor R, Raji A, Golm G, Huyck SB, Qiu Y, Sunga S, Johnson J, Terra SG, Mancuso JP, Engel SS, Lauring B. Pratley RE, et al. Diabetes Obes Metab. 2018 May;20(5):1111-1120. doi: 10.1111/dom.13194. Epub 2018 Jan 25. Diabetes Obes Metab. 2018. PMID: 29266675 Free PMC article. Clinical Trial.
211 results